{"id":36,"date":"2026-11-15T14:48:55","date_gmt":"2026-11-15T19:48:55","guid":{"rendered":"https:\/\/www.lisskron.com\/pans-pandas\/?p=36"},"modified":"2026-11-15T14:48:55","modified_gmt":"2026-11-15T19:48:55","slug":"cunningham-panel-neural-zoomer-pans-pandas","status":"publish","type":"post","link":"https:\/\/www.lisskron.com\/pans-pandas\/cunningham-panel-neural-zoomer-pans-pandas\/","title":{"rendered":"Cunningham Panel vs. Neural Zoomer for PANS\/PANDAS"},"content":{"rendered":"<p><strong>When a child changes, we need to investigate.<\/strong> Sudden changes in behavior, compulsions, tics, anxiety, food restriction or regression deserve a careful evaluation. In my Instagram post, I compared two blood-test panels families may hear about when discussing <a href=\"https:\/\/lisskron.com\/what-is-pans-pandas\/\">PANS\/PANDAS<\/a>: the Cunningham Panel and Neural Zoomer.<\/p>\n<aside class=\"liss-sources-panel\" aria-label=\"Join the conversation\">\n<p class=\"sources-title\">Let\u2019s talk about this together<\/p>\n<p>See the original slides about these panels, their results and the questions families are asking.<\/p>\n<p><a href=\"https:\/\/www.instagram.com\/p\/DemdxP1kYlD\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Join the Cunningham Panel and Neural Zoomer conversation \u2197<\/strong><\/a><\/p>\n<\/aside>\n<h2>What does the Cunningham Panel measure?<\/h2>\n<p>The Cunningham Panel\u2014now called the <a href=\"https:\/\/www.moleculera.com\/autoimmune-brain-panel-testing\/\" target=\"_blank\" rel=\"noopener noreferrer\">Autoimmune Brain Panel<\/a> by its laboratory\u2014contains five assays related to neuronal antibodies and CaMKII signaling activity. The slides group them this way:<\/p>\n<ul>\n<li><strong>Dopamine receptors D1 and D2:<\/strong> two antibody measurements.<\/li>\n<li><strong>Tubulin:<\/strong> an antibody measurement against a structural protein.<\/li>\n<li><strong>Lysoganglioside GM1:<\/strong> another neuronal antibody measurement.<\/li>\n<li><strong>CaMKII:<\/strong> a laboratory assay of cell-signaling activity stimulated by the patient\u2019s serum.<\/li>\n<\/ul>\n<p>Some clinicians use these results as complementary information when investigating possible immune involvement in neuropsychiatric symptoms. <strong>The panel does not confirm or rule out PANS\/PANDAS by itself.<\/strong> Results need to be considered alongside symptoms, medical history and other findings.<\/p>\n<h2>What is Neural Zoomer?<\/h2>\n<p>The carousel calls it \u201cNeuroZoomer Plus.\u201d Vibrant\u2019s product was named Neural Zoomer Plus and is now called <a href=\"https:\/\/vibrant-wellness.com\/tests\/neural-zoomer\" target=\"_blank\" rel=\"noopener noreferrer\">Neural Zoomer<\/a>. It is a commercial panel examining a broader range of antibodies related to the nervous system.<\/p>\n<ul>\n<li>It looks at antibodies associated with neural proteins and possible neurological autoimmunity.<\/li>\n<li>It may provide information for a clinician investigating an immune-related neurological concern.<\/li>\n<li>The clinician must decide whether the tested antibodies are relevant to the child\u2019s symptoms.<\/li>\n<\/ul>\n<p><strong>It is not a specific diagnostic test for PANS\/PANDAS.<\/strong> A broader panel does not replace a focused <a href=\"https:\/\/www.lisskron.com\/pans-pandas\/how-pans-pandas-is-diagnosed-tests-questions\/\">clinical evaluation<\/a>.<\/p>\n<h2>Medical use, insurance and IVIG<\/h2>\n<p>The post distinguishes the Cunningham Panel\u2019s use in PANS\/PANDAS discussions from Neural Zoomer\u2019s use in some functional-medicine settings. That is separate from whether an insurer will pay for testing or authorize IVIG.<\/p>\n<ul>\n<li><strong>Test coverage:<\/strong> ask about the exact panel before collection. Moleculera\u2019s <a href=\"https:\/\/www.moleculera.com\/pdf\/Insurance-checklist-1-2024.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">insurance checklist<\/a> says it is out of network and coverage cannot be guaranteed.<\/li>\n<li><strong>IVIG authorization:<\/strong> neither panel automatically secures approval. The treating specialist and insurer need to address the clinical case and the plan\u2019s requirements.<\/li>\n<li><strong>Keep the questions separate:<\/strong> \u201cWill this test help evaluate my child?\u201d and \u201cWhat will our insurance cover?\u201d require separate answers.<\/li>\n<\/ul>\n<h2>What if the result is positive?<\/h2>\n<p>A positive result can identify an abnormal measured marker. It does not automatically show that the marker is causing the symptoms. The slides ask the specialist to consider:<\/p>\n<ol>\n<li>Which symptoms the child has and when they began.<\/li>\n<li>Whether the clinical picture suggests autoimmune disease.<\/li>\n<li>Whether other studies support or contradict that explanation.<\/li>\n<li>Whether other neurological, infectious or immune causes need investigation.<\/li>\n<\/ol>\n<p><strong>The goal is an explanation that fits the child\u2014not simply a positive result.<\/strong><\/p>\n<h2>What if the result is negative?<\/h2>\n<ul>\n<li>A negative result does not automatically exclude PANS\/PANDAS.<\/li>\n<li>No single accepted biomarker confirms or excludes these conditions on its own.<\/li>\n<li>The evaluation still considers onset, symptom progression, medical history and appropriate investigations.<\/li>\n<\/ul>\n<p>Our <a href=\"https:\/\/www.lisskron.com\/pans-pandas\/pans-pandas-testing-guide-for-parents\/\">testing discussion guide<\/a> can help you prepare for that conversation.<\/p>\n<h2>Our children deserve answers<\/h2>\n<p>A previous autism diagnosis should not prevent investigation of <a href=\"https:\/\/www.lisskron.com\/pans-pandas\/pans-pandas-warning-signs-child-regression\/\">new symptoms or regression<\/a>. Families deserve professionals who listen, evaluate and explain their decisions. We need better research, diagnostic tools and access to specialists.<\/p>\n<blockquote>\n<p>We are looking for answers that help our children. With God beside us, we keep moving forward with faith, knowledge and perseverance.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>What the Cunningham Panel and Neural Zoomer measure, how to discuss positive or negative results, and what families should ask about insurance and IVIG.<\/p>\n","protected":false},"author":1,"featured_media":37,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,2],"tags":[],"class_list":["post-36","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diagnosis-care","category-pans-pandas-research"],"_links":{"self":[{"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/posts\/36","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/comments?post=36"}],"version-history":[{"count":1,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/posts\/36\/revisions"}],"predecessor-version":[{"id":39,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/posts\/36\/revisions\/39"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/media\/37"}],"wp:attachment":[{"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/media?parent=36"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/categories?post=36"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lisskron.com\/pans-pandas\/wp-json\/wp\/v2\/tags?post=36"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}